Deal News
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…
Eliem Therapeutics agrees to acquire Tenet
US-based Eliem Therapeutics has announced a definitive agreement for the acquisition of development-stage private biotechnology company Tenet Medicines. The acquisition…
Kintara and TuHURA enter merger deal to advance oncology pipeline
Kintara Therapeutics has signed a definitive agreement to execute an all-stock merger with TuHURA Biosciences to form a company for…
Aditxt to acquire Appili Therapeutics
Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common…
Eisai to divest rights for two therapies to Kaken
Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in…
Ingersoll Rand to expand life science presence with $2.3bn ILC buyout
Ingersoll Rand has signed an agreement for the acquisition of ILC Dover from investment company New Mountain Capital for $2.325bn…
Nuvation Bio to acquire AnHeart to form global oncology company
Nuvation Bio has made a definitive agreement to acquire AnHeart Therapeutics through an all-stock transaction, in a strategic move to…
AbbVie signs agreement to acquire Landos Biopharma for $212.5m
AbbVie has entered a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5m. The strategic acquisition boosts AbbVie's…
Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline
Novo Nordisk has agreed to acquire Germany-based Cardior Pharmaceuticals for up to €1bn ($1.1bn) to expand its cardiovascular pipeline. The…
Gilead acquires CymaBay Therapeutics for $4.3bn
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics for $4.3bn. The strategic move was finalised following the closure of…
